Between May 22, 2015, and March 12, 2018, in a randomized, open-label, noninferiority phase 3 trial, Nanoparticle albumin-bound (nab-)paclitaxel (100 mg/m2) on days 1, 8, and 15 of a 21-day cycle, were applied for patients with advanced NSCLC previously treated with cytotoxic chemotherapy. Here, ALB is linked to non-small cell lung carcinoma.